Selpercatinib: Targeted Therapy For Ret Fusion-Positive Nsclc – Dosage, Side Effects, Storage &Amp; Handling
Selpercatinib, a targeted therapy, is indicated for treating RET fusion-positive non-small cell lung cancer (NSCLC). Patients should receive the recommended dosage schedule, considering potential interactions with other medications. Common adverse effects include cardiac toxicity, hypertension, and hepatic impairment. However, proper storage and handling are essential for maintaining the drug’s stability and efficacy. Selpercatinib: A Targeted…